Status:

ENROLLING_BY_INVITATION

Whole Blood Transcriptomic Signal According to Coronary Atherosclerotic Plaque Burden Assessed by CT Angiography

Lead Sponsor:

MultiplAI Health Limited

Collaborating Sponsors:

Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia

Conditions:

Calcific Coronary Arteriosclerosis

Coronary Stenosis

Eligibility:

All Genders

18-75 years

Brief Summary

The present clinical study aims to identify transcriptomic patterns derived from whole blood samples related to coronary atherotic burden. Additionally, as a secondary analysis, the research team will...

Detailed Description

This will be a prospective observational study. A convenience sample will be carried out to include 200 patients who attend the ENERI Medical Institute, La Sagrada Familia Clinic and Sanatorio Mendez ...

Eligibility Criteria

Inclusion

  • Men and women between 18 and 75 years, with a clinical indication to be evaluated by a CCTA due to suspected or known CAD.
  • Signature of informed consent.

Exclusion

  • Previously known chronic renal or hepatic insufficiency.
  • Active chronic lung disease, defined as: exacerbated asthma, exacerbated COPD, or pulmonary fibrosis.
  • Myocardial infarction, unstable angina, cerebrovascular accident, or vascular interventions (any territory) in the past 6 months.
  • Implantation of drug-eluting stents in the last 12 months.
  • Revascularization surgery (By-pass)
  • Indication of Angio-CT for congenital heart disease or Transcatheter Aortic Valve Replacement (TAVI)
  • Presence/ diagnosis of heart failure symptoms or signs (ie. dyspnea, asthenia, edema) with objective evidence of pulmonary or systemic congestion at rest or with exercise in the last 6 months.
  • Left ventricular ejection fraction \<50% confirmed by objective diagnostic methods (eg doppler echocardiogram).
  • Severe valvulopathies, confirmed by objective diagnostic methods (eg doppler echocardiogram).
  • Uncontrolled hyper or hypothyroidism.
  • Suprarenal insufficiency.
  • Previous surgeries in the last 3 months.
  • Severe trauma in the last 6 months, defined as one that involved bone fractures and/or surgical interventions.
  • Known active cancer disease or under treatment (acute or preventive), or history of cancer disease without criteria for cure.
  • Diagnosis of active autoimmune disease or any pathology under immunosuppressive treatment.
  • Ongoing pregnancy, postpartum period of less than 12 months or breastfeeding.
  • Other serious diseases with an estimated life expectancy of less than 12 months (according to the investigator's opinion).
  • Temperature greater than 37.5°C recorded by a thermometer or any acute infection caused by viruses or bacteria confirmed by a health professional in the previous 30 days.
  • Pacemaker/Cardio-Defibrillator Implantation.
  • Prior to the study: heart rate \> 70 l/m or atrial fibrillation or frequent extrasystoles that in the opinion of the specialist physician will affect the quality of the cardiovascular imaging.

Key Trial Info

Start Date :

September 19 2023

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

September 1 2028

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT06194526

Start Date

September 19 2023

End Date

September 1 2028

Last Update

January 8 2024

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Sanatorio Julio Mendez

Ciudad Autónoma de Buenos Aire, Buenos Aires F.D., Argentina, 1405

2

Clinica Sagrada Familia

Ciudad Autónoma de Buenos Aire, Buenos Aires F.D., Argentina, 1425